<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449930</url>
  </required_header>
  <id_info>
    <org_study_id>0431-049</org_study_id>
    <secondary_id>MK0431-049</secondary_id>
    <secondary_id>2006_561</secondary_id>
    <nct_id>NCT00449930</nct_id>
  </id_info>
  <brief_title>Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used
      medication in patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2007</start_date>
  <completion_date type="Actual">July 25, 2008</completion_date>
  <primary_completion_date type="Actual">July 25, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0431</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: metformin hydrochloride</intervention_name>
    <description>(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus (T2DM)

          -  Patient is inadequately controlled and not on treatment with insulin or oral
             antihyperglycemic therapy

        General Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Mar;12(3):252-61. doi: 10.1111/j.1463-1326.2009.01187.x. Epub 2009 Nov 25.</citation>
    <PMID>20070351</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <results_first_submitted>June 23, 2009</results_first_submitted>
  <results_first_submitted_qc>June 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2009</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient In: 04-Apr-2007
Last Patient Last Visit: 25-Jul-2008
113 study centers worldwide</recruitment_details>
      <pre_assignment_details>Patients 18-78 years of age with Type 2 diabetes mellitus (T2DM) who were not on anti-hyperglycemic agents for at least 4 months (16 weeks) and with a hemoglobin A1c (HbA1c) of ≥ 6.5 and ≤9.0%</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="528"/>
                <participants group_id="P2" count="522"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="467"/>
                <participants group_id="P2" count="447"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Terminated ( Site Closed)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Glycemic discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="528"/>
            <count group_id="B2" value="522"/>
            <count group_id="B3" value="1050"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="10.7"/>
                    <measurement group_id="B2" value="56.1" spread="10.4"/>
                    <measurement group_id="B3" value="56.0" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="566"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.9" spread="17.7"/>
                    <measurement group_id="B2" value="84.6" spread="17.2"/>
                    <measurement group_id="B3" value="84.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="0.7"/>
                    <measurement group_id="B2" value="7.3" spread="0.7"/>
                    <measurement group_id="B3" value="7.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24</title>
        <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>The per protocol population required that a patient had measurements both at baseline and at Week 24, and did not have any major protocol violations (e.g. drug compliance &lt;85%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24</title>
          <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.</description>
          <population>The per protocol population required that a patient had measurements both at baseline and at Week 24, and did not have any major protocol violations (e.g. drug compliance &lt;85%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" lower_limit="-0.48" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-0.62" upper_limit="-0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pre-specified non-inferiority margin was 0.4%; i.e., non-inferiority required that the upper boundary of the 95% confidence interval for the treatment difference (sitagliptin minus metformin) to be less than 0.4%.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>Based on an analysis of covariance (ANCOVA) model with terms for treatment group and baseline value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea</title>
          <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients Who Reported Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Did Not Report Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509"/>
                    <measurement group_id="O2" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
            <estimate_desc>Difference (sitagliptin minus metformin) in the percentage of patients with diarrhea.
Wilson Score method was used for the 95% Confidence Interval (CI).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea</title>
          <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients Who Reported Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Did Not Report Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522"/>
                    <measurement group_id="O2" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Difference (sitagliptin minus metformin) in the percentage of patients with nausea.
Wilson Score method was used for the 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain</title>
          <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients Who Reported Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Did Not Report Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517"/>
                    <measurement group_id="O2" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Difference (sitagliptin minus metformin) in the percentage of patients with abdominal pain.
Wilson Score method was used for the 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting</title>
          <population>All randomized patients who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients Who Reported Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Did Not Report Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526"/>
                    <measurement group_id="O2" value="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Difference (sitagliptin minus metformin) in the percentage of patients with vomiting.
Wilson Score method was used for the 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablet of sitagliptin once daily.</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>The Metformin group includes data from patients randomized to receive treatment with metformin initiated at a dose of 1 tablet (500 mg) per day. Patients were then to be up-titrated over a maximum of 5 weeks to a total daily dose of 2 tablets twice daily (1000 mg b.i.d).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10"/>
                <counts group_id="E2" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Any Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Any Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Multiple endocrine adenomatosis Type II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Any Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Intervertebral disc injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Any Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Hydrometra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
                <counts group_id="E2" subjects_affected="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="528"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Site 0490125 was non-compliant with Good Clinical Practice (GCP). Data from the 8 patients at this site were removed from all analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

